Accessibility Menu
 
Biodexa Pharmaceuticals Plc logo

Biodexa Pharmaceuticals Plc

(NASDAQ) BDRX

Current Price$3.49
Market Cap$1.76M
Since IPO (2015)-100%
5 Year-100%
1 Year-94%
1 Month+14%

Biodexa Pharmaceuticals Plc Financials at a Glance

Market Cap

$1.76M

Revenue (TTM)

$0.00

Net Income (TTM)

$12.10M

EPS (TTM)

$-103.95

P/E Ratio

-0.04

Dividend

$0.00

Beta (Volatility)

1.03 (Average)

Price

$3.49

Volume

28,401.4

Open

$3.77

Previous Close

$3.42

Daily Range

$3.41 - $3.77

52-Week Range

$2.86 - $96.50

BDRX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Biodexa Pharmaceuticals Plc

Industry

Biotechnology

Employees

11

CEO

Stephen Anthony Stamp

Headquarters

Cardiff, CF10 4DQ, GB

BDRX Financials

Key Financial Metrics (TTM)

Gross Margin

0%

Operating Margin

0%

Net Income Margin

0%

Return on Equity

-65%

Return on Capital

-73%

Return on Assets

-35%

Earnings Yield

-25.00%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.76M

Shares Outstanding

451.60K

Volume

28.40K

Short Interest

0.00%

Avg. Volume

458.37K

Financials (TTM)

Gross Profit

$184.86K

Operating Income

$8.27M

EBITDA

$8.08M

Operating Cash Flow

$5.39M

Capital Expenditure

$1.96K

Free Cash Flow

$5.40M

Cash & ST Invst.

$8.52M

Total Debt

$60.89K

Biodexa Pharmaceuticals Plc Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$0.00

-100.0%

Gross Profit

$48.70K

+97.8%

Gross Margin

0.00%

N/A

Market Cap

$1.76M

N/A

Market Cap/Employee

$135.15K

N/A

Employees

13

N/A

Net Income

$2.56M

+27.0%

EBITDA

$4.68M

-104.5%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$8.46M

+53.6%

Accounts Receivable

$221.61K

-68.5%

Inventory

$0.00

N/A

Long Term Debt

$0.00

-100.0%

Short Term Debt

$60.89K

-64.0%

Return on Assets

-35.09%

N/A

Return on Invested Capital

-72.66%

N/A

Free Cash Flow

$2.33M

+21.6%

Operating Cash Flow

$2.33M

+21.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
GNPXGenprex, Inc.
$1.02+0.00%
CANFCan-Fite BioPharma Ltd.
$2.91-1.69%
CNSPCNS Pharmaceuticals, Inc.
$2.47+0.82%
INMInMed Pharmaceuticals Inc.
$0.76-1.93%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$10.33+0.05%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$12.02-0.07%
QSQuantumScape
$7.41+0.01%
TQQQProShares Trust - ProShares UltraPro Qqq
$59.22-0.02%

Questions About BDRX

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.